Catalyst Wire Dossier Catalyst Wire Dossier

Solymbic

adalimumab · Amgen Europe B.V.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Solymbic, covering 2019-03-05 to 2019-03-05. Get the full timeline:

Most recent: EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.

See pricing